Needham initiated coverage of Tempus AI with a Buy rating and $47 price target. The analyst expects the company’s “unique approach” to support share gains in a total addressable market sized at nearly $200B could drive long-term annual sales growth at 30%-plus “even though the company’s business already boasts impressive scale.” The firm says Tempus AI’s margin-accretive data revenue will widen its gross margin and push the company toward breakeven EBITDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Largest borrow rate increases among liquid names
- CMS awards Tempus AI with ADLT status for xT CDx test
- Tempus AI receives 510(k) clearance for Tempus ECG-AF
- Tempus AI, United Therapeutics collaborate to study use of AI to detect PH risk
- Tempus AI receives 510(k) Premarket Notification for Tempus ECG-AF